uu.seUppsala University Publications
Change search
ReferencesLink to record
Permanent link

Direct link
Biliary Excretion of Ximelagatran and Its Metabolites and the Influence of Erythromycin Following Intraintestinal Administration to Healthy Volunteers
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Pharmacy, Department of Pharmacy.
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Surgical Sciences.
Show others and affiliations
2011 (English)In: Journal of clinical pharmacology, ISSN 0091-2700, E-ISSN 1552-4604, Vol. 51, no 5, 770-783 p.Article in journal (Refereed) Published
Abstract [en]

The biliary excretion of the oral thrombin inhibitor ximelagatran and its metabolites was investigated by using duodenal aspiration in healthy volunteers following intraintestinal dosing. In the first investigation, radiolabeled [C-14] ximelagatran was administered, enabling quantification of the biliary excretion and identification of metabolites in the bile. In the second study, the effect of erythromycin on the biliary clearance of ximelagatran and its metabolites was investigated to clarify the reported ximelagatran-erythromycin interaction. Approximately 4% of the intraintestinal dose was excreted into bile with ximelagatran and its active form, melagatran, being the most abundant compounds. Four novel ximelagatran metabolites were identified in bile (< 0.1% of dose). Erythromycin changed the pharmacokinetics of ximelagatran and its metabolites, with an elevated ximelagatran (78% increase), OH-melagatran (89% increase), and melagatran (86% increase) plasma exposure and higher peak plasma concentrations of the compounds being measured. In parallel, the biliary clearance was moderately reduced. The results suggest that inhibition of hepatobiliary transport is a likely mechanism for the interaction between erythromycin and ximelagatran. Furthermore, the study demonstrated the value of direct bile sampling in humans for the identification of primary biliary metabolites.

Place, publisher, year, edition, pages
2011. Vol. 51, no 5, 770-783 p.
Keyword [en]
hepatobiliary transport, biliary clearance, drug-drug interaction, ximelagatran, erythromycin, direct thrombin inhibitors
National Category
Pharmaceutical Sciences
Research subject
URN: urn:nbn:se:uu:diva-123416DOI: 10.1177/0091270010370975ISI: 000289942400016PubMedID: 20663994OAI: oai:DiVA.org:uu-123416DiVA: diva2:313921
Available from: 2010-04-27 Created: 2010-04-27 Last updated: 2011-05-16Bibliographically approved

Open Access in DiVA

No full text

Other links

Publisher's full textPubMed

Search in DiVA

By author/editor
Matsson, Elin
By organisation
Department of PharmacyDepartment of Surgical Sciences
In the same journal
Journal of clinical pharmacology
Pharmaceutical Sciences

Search outside of DiVA

GoogleGoogle Scholar
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

Altmetric score

Total: 197 hits
ReferencesLink to record
Permanent link

Direct link